Daiichi Sankyo

Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo is a global pharmaceutical company headquartered in Tokyo, Japan. The company is engaged in two main business categories: Pharmaceuticals and Over-the-Counter (OTC) drugs. Its pharmaceutical segment focuses on multiple therapeutic areas, such as oncology, cardiovascular diseases, metabolic disorders, infectious diseases, and vaccines. In its portfolio, Daiichi Sankyo boasts a list of important brands that have solidified their presence in the pharmaceutical industry. This includes Lixiana or Savaysa (Edoxaban), an anticoagulant; Bonoteo (Minodronic acid), which is used to treat osteoporosis; Minnebro (Esaxerenone), prescribed for hypertension; Namenda (Memantine), which is offered in certain markets for Alzheimer's disease; and Tenelia (Teneligliptin), a medication for diabetes. With a global operational footprint, Daiichi Sankyo has key markets across numerous regions, including its home country of Japan, the United States, the European Union, and it is increasing its presence in China and other parts of Asia. (Powered by AI)